KPTI

Karyopharm Therapeutics is an oncology-focused pharmaceutical company developing novel drugs using Selective Inhibitor of Nuclear Export (SINE) technology. The company's lead product, selinexor, is approved for multiple cancer indications including multiple myeloma and diffuse large B-cell lymphoma. Karyopharm is advancing additional SINE compounds through clinical development for various hematologic and solid tumor malignancies.